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ABSTRACT
OBJECTIVE
To evaluate the effects of therapeutic heparin 
compared with prophylactic heparin among 
moderately ill patients with covid-19 admitted to 
hospital wards.
DESIGN
Randomised controlled, adaptive, open label clinical 
trial.
SETTING
28 hospitals in Brazil, Canada, Ireland, Saudi Arabia, 
United Arab Emirates, and US.
PARTICIPANTS
465 adults admitted to hospital wards with covid-19 
and with increased D-dimer levels were recruited 
between 29 May 2020 and 12 April 2021 and were 
randomly assigned to therapeutic dose heparin 
(n=228) or prophylactic dose heparin (n=237).
INTERVENTIONS
Therapeutic dose or prophylactic dose heparin (low 
molecular weight or unfractionated heparin), to be 
continued until hospital discharge, day 28, or death.
MAIN OUTCOME MEASURES
The primary outcome was a composite of death, 
invasive mechanical ventilation, non-invasive 
mechanical ventilation, or admission to an intensive 
care unit, assessed up to 28 days. The secondary 
outcomes included all cause death, the composite 
of all cause death or any mechanical ventilation, 
and venous thromboembolism. Safety outcomes 
included major bleeding. Outcomes were blindly 
adjudicated.
RESULTS
The mean age of participants was 60 years; 264 
(56.8%) were men and the mean body mass index 
was 30.3 kg/m2. At 28 days, the primary composite 
outcome had occurred in 37/228 patients (16.2%) 
assigned to therapeutic heparin and 52/237 (21.9%) 
assigned to prophylactic heparin (odds ratio 0.69, 
95% confidence interval 0.43 to 1.10; P=0.12). 
Deaths occurred in four patients (1.8%) assigned to 
therapeutic heparin and 18 patients (7.6%) assigned 
to prophylactic heparin (0.22, 0.07 to 0.65; P=0.006). 
The composite of all cause death or any mechanical 
ventilation occurred in 23 patients (10.1%) assigned 
to therapeutic heparin and 38 (16.0%) assigned to 
prophylactic heparin (0.59, 0.34 to 1.02; P=0.06). 
Venous thromboembolism occurred in two patients 
(0.9%) assigned to therapeutic heparin and six (2.5%) 
assigned to prophylactic heparin (0.34, 0.07 to 1.71; 
P=0.19). Major bleeding occurred in two patients 
(0.9%) assigned to therapeutic heparin and four 
(1.7%) assigned to prophylactic heparin (0.52, 0.09 to 
2.85; P=0.69).
CONCLUSIONS
In moderately ill patients with covid-19 and increased 
D-dimer levels admitted to hospital wards, therapeutic 
heparin was not significantly associated with a 
reduction in the primary outcome but the odds of 
death at 28 days was decreased. The risk of major 
bleeding appeared low in this trial.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Randomised trials suggest that therapeutic heparin is beneficial in moderately ill 
patients with covid-19 admitted to hospital, but of no benefit and potential harm 
when provided to critically ill patients
Given the disparate findings in these two patient populations, there is hesitancy to 
adopt therapeutic heparin as standard care in moderately ill patients with covid-19
WHAT THIS STUDY ADDS
Use of therapeutic heparin in moderately ill patients with covid-19 and increased 
D-dimer levels admitted to hospital wards was not associated with a significant 
reduction in the primary composite outcome of death, non-invasive or invasive 
mechanical ventilation, or ICU admission
Although the difference in the primary outcome was not statistically significant, 
a noticeable reduction in mortality and low risk of bleeding was observed with 
therapeutic heparin
 on 19 O












J: first published as 10.1136/bm






2 doi: 10.1136/bmj.n2400 | BMJ 2021;375:n2400 | the bmj
Introduction
The most common cause of clinical deterioration 
of patients admitted to hospital with covid-19 
is hypoxaemic respiratory failure.1 Pulmonary 
endothelial injury and microvascular thrombosis 
probably contribute to respiratory compromise,2-6 
which in turn might be caused by a thrombo-
inflammatory state, also referred to as covid-19 
coagulopathy.2 3 7-9 Increased D-dimer levels in the 
blood, as a marker of coagulopathy, and hypoxaemia 
are associated with poor prognosis.2 3 7-10
Heparin, in addition to its anticoagulant properties, 
has anti-inflammatory and potential antiviral effects 
and might improve endothelial function.2 11-15 Early 
initiation of therapeutic heparin could therefore 
decrease the thrombo-inflammatory process and 
reduce the risk of critical illness or death.2 4 16-18 
Randomised trials indicated that anticoagulation 
using therapeutic heparin might be beneficial in 
moderately,19 but not critically20 ill patients with 
covid-19, suggesting that the time of initiation of 
therapeutic heparin is important. The Therapeutic 
Anticoagulation versus Standard Care as a Rapid 
Response to the COVID-19 Pandemic (RAPID) trial 
was designed to determine if therapeutic heparin 
is superior to prophylactic heparin in moderately 
ill patients with covid-19 and increased D-dimer 
levels admitted to hospital wards in decreasing the 
composite of admission to an intensive care unit 
(ICU), mechanical ventilation, or death.
Methods
Trial oversight
The RAPID trial was an investigator initiated 
randomised controlled trial. For administrative reasons, 
the protocol in Brazil was registered separately, but 
prospectively harmonised (see supplementary file). 
An independent data and safety monitoring board 
oversaw the trial (see supplementary file).
Design
The RAPID trial was an investigator initiated, 
parallel, pragmatic, adaptive multicentre, open label 
randomised controlled trial conducted at 28 hospitals 
in six countries. Its design has been described 
previously and the study protocol and statistical 
analysis plan are provided in the supplementary file.21 
The trial evaluates the effects of therapeutic heparin 
compared with prophylactic heparin in moderately ill 
patients with covid-19 admitted to hospital.
Trial population
Patients were eligible if they were moderately ill 
and admitted to hospital wards for covid-19 with 
laboratory confirmed SARS-CoV-2 infection and had 
increased D-dimer levels within the first five days of 
admission. Moderate illness was defined as admission 
to hospital ward level of care (ie, not to ICU), not 
already mechanically ventilated, and not imminently 
requiring mechanical ventilation or critical care. 
D-dimer levels were required to be above the upper 
limit of normal of the local hospital in the presence 
of an oxygen saturation ≤93% on room air, or ≥2 
times the upper limit of normal irrespective of oxygen 
saturation. Participants were excluded if they had 
substantial bleeding risks, an absolute indication for 
or any contraindication to heparin anticoagulation 
based on care team judgment, were pregnant, or if 
they had already experienced, or would imminently 
experience any component of the primary outcome 
(all cause death, non-invasive or invasive mechanical 
ventilation, or ICU admission). Full eligibility criteria 
are provided in the supplementary file. Written 
informed consent was obtained from all participants 
or their legal representatives.
Randomisation and study drugs
We used web based central randomisation with a 
computer generated random sequence of variable 
block sizes stratified by site and age (≤65 v >65 
years) to assign patients in a 1:1 ratio to therapeutic 
heparin or prophylactic heparin. Throughout the 
paper heparin refers to either low molecular weight 
heparin or unfractionated heparin—both forms of 
heparin are within the same drug class and exert 
their anticoagulant effect by amplifying the activity 
of the coagulation inhibitor antithrombin. They 
both also have similar non-anticoagulant effects.22 
Patients allocated to therapeutic heparin received 
therapeutic doses of low molecular weight heparin or 
unfractionated heparin as used for the treatment of 
venous thromboembolism.23 Unfractionated heparin 
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was administered using a weight based nomogram 
(bolus plus continuous infusion) with activated partial 
thromboplastin time or unfractionated heparin anti-
Xa titration according to the centre specific protocols 
(that is, high dose nomogram). Patients allocated to 
prophylactic heparin received dose capped prophylactic 
subcutaneous heparin (low molecular weight heparin 
or unfractionated heparin) adjusted for body mass 
index and creatinine clearance (see supplementary 
file for dosing). Prophylactic doses of heparin were 
thus restricted to evidence based protocols for the 
prevention of venous thromboembolism for medical 
patients admitted to hospital.24 Study treatment was 
started within 24 hours after randomisation and 
continued until the first of hospital discharge, day 28, 
study withdrawal, or death (supplementary fig S1). If 
a participant was admitted to ICU, continuation of the 
allocated treatment was recommended.
Study outcomes
The primary outcome was a composite of ICU 
admission, non-invasive (bilevel or continuous positive 
airway pressure) or invasive mechanical ventilation, 
or death up to 28 days. Secondary outcomes included 
all cause death; the composite of any mechanical 
ventilation or all cause death; ICU admission or 
all cause death; ventilator-free days alive; organ 
support-free days alive; ICU-free days alive; hospital-
free days alive; renal replacement therapy; venous 
thromboembolism; arterial thromboembolism; and 
D-dimer level from blood samples taken at two days 
±24 hours post-randomisation (see the supplementary 
file for detailed definitions). The following components 
of the primary composite were not included in 
the protocol but were prespecified as secondary 
outcomes in the statistical analysis plan: invasive 
mechanical ventilation; composite of invasive or non-
invasive mechanical ventilation; and ICU admission. 
Prespecified safety outcomes included major bleeding 
as defined by the International Society on Thrombosis 
and Haemostasis,25 red blood cell transfusion (≥1 
unit), transfusion of haemostatic blood components or 
products, and heparin induced thrombocytopenia. If a 
patient reached any defined clinical endpoint (that is, 
component of primary outcome or secondary outcome), 
other than events that required a change to clinical care, 
such as thromboembolism or bleeding, the protocol 
suggested ongoing treatment per allocated arm but left 
ultimate decisions about heparin anticoagulation to 
the discretion of the treating doctors. An independent 
event adjudication committee, which was unaware of 
treatment assignments, adjudicated the components 
of the primary outcome, bleeding, thrombotic events, 
and cause of death. The event adjudication was not 
prespecified in the protocol.
Statistical analysis
We estimated that 231 patients in each group would 
provide 90% power to detect a 15% absolute risk 
difference, from 50% in the control group to 35% in 
the experimental group, at a two sided α level of 0.048 
accounting for two planned interim analyses at 25% 
and 75% of the originally planned sample size.2 16 21 At 
75%, we performed a conditional power analysis. The 
protocol prespecified that the sample size would be 
increased if the conditional power was between 60% 
and 80%.21 As the conditional power was below 60%, 
the data safety and monitoring board recommended not 
to increase the sample size and complete recruitment 
as originally planned.
The primary analysis of the primary composite 
outcome was based on the intention-to-treat principle 
using logistic regression; a χ2 test of independence 
was conducted to obtain a two sided P value.26 
Participants who did not have a 28 day assessment 
but were discharged from hospital alive before 
day 28, were assumed to be event-free up to day 
28. Prespecified subgroup analyses of the primary 
outcome accompanied by tests of interaction were 
done for age, sex, body mass index, time from onset 
of covid-19 symptoms, diabetes mellitus, coronary 
artery disease, hypertension, race or ethnicity, D-dimer 
level, use of systemic corticosteroids, and geographical 
region. Post hoc subgroup analyses were repeated 
for all cause death. Prespecified sensitivity analyses 
of the primary outcome excluded participants who 
did not have a 28 day assessment and included only 
participants from the per protocol cohort. The per 
protocol cohort included all eligible participants who 
received their intervention as randomly allocated 
during the first 48 hours after randomisation, and 
excluded participants who did not satisfy all eligibility 
criteria, did not receive their allocated treatment, or did 
not have follow-up until day 28, death, or occurrence 
of a primary composite outcome component. Since 
randomisation was stratified by age, an additional 
logistic regression model was fit to analyse the primary 
outcome controlling for age.
Binary secondary outcomes were analysed using 
logistic regression. Ventilator-free days, organ support-
free days, ICU-free days, and hospital-free days alive 
were analysed using ordinal logistic regression; 
death up to 28 days was assigned the worst outcome 
(a value of −1) in these analyses.27 We compared the 
post-treatment D-dimer level using linear regression 
adjusted for baseline. Since D-dimer assays differed 
across sites, D-dimer levels were expressed as 
multiples of the local laboratory assay upper limit of 
normal (D-dimer×upper limit of normal)—that is, the 
ratio of D-dimer values divided by the local upper limit 
of normal, and analysed as natural logarithm of this 
ratio: log(D-dimer/upper limit of normal). Analyses of 
secondary outcomes were considered exploratory so 
were not adjusted for multiple comparisons; the widths 
of 95% confidence intervals for secondary outcomes 
should not be used for inferences about treatment 
effects. The supplementary file provides an extended 
description of the statistical methods.
Patient and public involvement
Funding limitations and covid-19 restrictions 
interfered with our ability to involve patient partners in 
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setting the research question and in developing plans 
for recruitment, design, and implementation of the 
results of this study.
Results
From 29 May 2020 to 12 April 2021, a total of 3975 
patients were screened and 465 included in the study: 
228 were randomly assigned to therapeutic heparin 
and 237 to prophylactic heparin. Overall, 224 (98.2%) 
in the therapeutic heparin group and 234 (98.7%) in 
the prophylactic heparin group received treatment as 
allocated within 24 hours after randomisation, and 
222 (97.4%) and 232 (97.9%), respectively, continued 
to receive treatment as allocated up to 48 hours after 
randomisation (fig 1). The final follow-up date for the 
28 day primary outcome was 10 May 2021.
The mean age of participants was 60 years; 264 
(56.8%) were men and the mean body mass index 
was 30.3. Baseline D-dimer level was 2.3-fold above 
the upper limit of normal, and mean creatinine 
was 85.2 µmol/L. At baseline, six patients in the 
therapeutic heparin group and five in the prophylactic 
heparin group had D-dimer levels below the upper 
limit of normal. Baseline personal and clinical 
characteristics were similar between treatment arms 
(table 1, and supplementary tables S1-2). The mean 
duration from symptom onset to hospital admission 
was 7.1 days, and the mean duration from hospital 
admission to randomisation was 1.4 days. The mean 
treatment duration was 6.5 in the therapeutic heparin 
group and 6.3 days in the prophylactic heparin 
group (supplementary table S3). One patient in the 
therapeutic heparin group was admitted to hospital for 
more than 28 days post-randomisation compared with 
none in the prophylactic heparin group. Low molecular 
weight heparin was prescribed in 224 (98.2%) patients 
assigned to therapeutic heparin and 222 (93.7%) 
assigned to prophylactic heparin. Concomitant 
treatments (systemic corticosteroids, remdesivir, and 
tocilizumab) were balanced between treatment arms 
for pre-randomisation and post-randomisation periods 
combined (supplementary table S4).
Effectiveness outcomes
The primary outcome occurred in 37 patients (16.2%) 
in the therapeutic heparin group and 52 (21.9%) 
Assessed for eligibility
Excluded
No laboratory confirmed covid-19
Negative D-dimer result*






Allocated to therapeutic heparin
Received allocated intervention
Did not receive allocated intervention†
    Clinician discretion












Intention to treat analysis
Per protocol analysis
Excluded from per protocol analysis
    Did not receive allocated intervention†






Intention to treat analysis
Per protocol analysis
Excluded from per protocol analysis
    Did not receive allocated intervention†






Allocated to prophylactic heparin
Received allocated intervention
Did not receive allocated intervention†





Did not meet component of primary composite
  outcome, discharged from hospital alive, but
  lost to telephone follow-up at 28 days
4
Lost to follow-up aer hospital discharge
7
Did not meet component of primary composite
  outcome, discharged from hospital alive, but
  lost to telephone follow-up at 28 days
7
Fig 1 | Screening, enrolment, randomisation, and inclusion in analysis. *Six patients in the therapeutic heparin 
group and five in the prophylactic heparin group had negative D-dimer values at the time of randomisation due to a 
delay in protocol harmonisation with Brazil. †Did not receive allocated intervention within the first 48 hours post-
randomisation without clear clinical indication
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Table 1 | Baseline characteristics of moderately ill patients with covid-19 admitted to hospital wards, according to treatment assignment. Values are 
numbers (percentages) unless stated otherwise
Characteristics Therapeutic heparin (n=228) Prophylactic heparin (n=237)
Mean (SD) age (years) 60.4 (14.1) 59.6 (15.5)
Women 105 (46.1) 96 (40.5)
Men 123 (53.9) 141 (59.5)
Race or ethnicity*:
 White
 European 97 (43.7) 96 (40.9)
 Middle Eastern, North African 65 (29.3) 67 (28.5)
 Asian 27 (12.2) 38 (16.2)
 Black or African American 18 (8.1) 23 (9.8)
 Hispanic or Latino 14 (6.3) 10 (4.3)
   American Indian, Alaska Native, First Nations, Indigenous/Aboriginal, Metis 0 (0.0) 1 (0.4)
 Native Hawaiian or Other Pacific Islander 1 (0.5) 0 (0.0)
Mean (SD) body mass index† 30.3 (6.4) 30.2 (7.0)
Mean (SD) duration of symptoms before hospital admission (days)‡ 7.1 (5.1) 7.1 (5.2)
Mean (SD) duration of hospital admission before randomisation (days) 1.5 (1.1) 1.4 (1.0)
Hypoxaemia at baseline§ 190 (90.9) 203 (93.1)
High flow nasal cannula oxygen use 14 (6.2) 13 (5.5)
Pre-existing conditions:
 Hypertension 108 (47.4) 117 (49.4)
 Diabetes mellitus 83 (36.4) 77 (32.5)
 Coronary artery disease 16 (7.0) 18 (7.6)
 Heart failure 9 (3.9) 6 (2.5)
 Atrial fibrillation 0 (0.0) 2 (0.8)
 Cerebrovascular disease 10 (4.4) 9 (3.8)
 Peripheral vascular disease 0 (0.0) 1 (0.4)
 History of venous thromboembolism 3 (1.3) 2 (0.8)
 Chronic pulmonary disease¶ 36 (15.8) 27 (11.4)
 Chronic kidney disease 20 (8.8) 13 (5.5)
 Chronic liver disease 5 (2.2) 9 (3.8)
 Cancer 13 (5.7) 19 (8.0)
 Immunodeficiency 1 (0.4) 2 (0.8)
 Autoimmune disease 6 (2.6) 11 (4.6)
 Cognitive impairment 12 (5.3) 11 (4.6)
 Mental illness 18 (7.9) 13 (5.5)
Active smoking 5 (2.2) 7 (3.0)
Drug history**:
 Systemic corticosteroids 161 (70.6) 162 (68.4)
 Antiplatelet agent 24 (10.5) 29 (12.2)
Previous covid-19 vaccine 1 (0.4) 2 (0.8)
Laboratory values:
 D-dimer
  D-dimer positivity†† 222 (97.4) 232 (97.9)
  Geometric mean (SD) D-dimer ratio (D-dimer×ULN)‡‡ 2.1 (0.7) 2.5 (0.9)
D-dimer distribution:
 <2×ULN 115 (50.4) 112 (47.3)
 ≥2-3×ULN 61 (26.8) 55 (23.2)
 ≥3-4×ULN 25 (11.0) 27 (11.4)
 ≥4×ULN 27 (11.8) 43 (18.1)
Mean (SD) platelet count (109/L)§§ 233.7 (95.7) 237.8 (95.3)
Mean (SD) creatinine (μmol/L)¶¶ 84.6 (44.1) 85.9 (58.2)
Country:
 Brazil 54 (23.7) 51 (21.5)
 Canada 72 (31.6) 78 (32.9)
 Ireland 11 (4.8) 12 (5.1)
 Saudi Arabia 71 (31.1) 76 (32.1)
 United Arab Emirates 7 (3.1) 6 (2.5)
 USA 13 (5.7) 14 (5.9)
Enrolled in another covid-19 trial 29 (12.7) 31 (13.1)
BMI=body mass index; SD=standard deviation; ULN=upper limit of normal.
*Data were missing for six patients in the therapeutic heparin group and two in the prophylactic heparin group.
†Data were missing for six participants in the therapeutic heparin group and four in the prophylactic heparin group.
‡Data were missing for one patient in the therapeutic heparin group and five patients in the prophylactic heparin group.
§Hypoxaemia was defined as oxygen saturation <93% on room air. Data were missing for 19 patients in the therapeutic heparin group and 19 in the prophylactic heparin group.
¶Includes chronic restrictive pulmonary disease, chronic obstructive pulmonary disease, and asthma.
**No patients were on remdesivir or tocilizumab at baseline.
††Six patients in the therapeutic heparin group and five in the prophylactic heparin group had D-dimer levels below the ULN.
‡‡SD for the natural logarithm of D-dimer ratios (D-dimer levels×ULN).
§§Data were missing for 16 patients in the therapeutic heparin group and 24 in the prophylactic heparin group.
¶¶Data were missing for 14 patients in the therapeutic heparin group and 23 in the prophylactic heparin group.
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in the prophylactic heparin group (odds ratio 0.69, 
95% confidence interval 0.43 to 1.10, P=0.12; table 
2 and supplementary table S5). Death from any cause 
occurred in four patients (1.8%) in the therapeutic 
heparin group and 18 (7.6%) in the prophylactic 
heparin group (0.22, 0.07 to 0.65; P=0.006). 
Hypoxaemic respiratory failure was the most common 
cause of death (supplementary table S6). The composite 
of invasive or non-invasive mechanical ventilation 
occurred in 21 patients (9.2%) in the therapeutic 
heparin group and 26 (11.0%) in the prophylactic 
heparin group (0.82, 0.45 to 1.51; P=0.53). ICU 
admission occurred in 33 patients (14.5%) in the 
therapeutic heparin group and 42 (17.7%) in the 
prophylactic heparin group (0.79, 0.48 to 1.29; 
P=0.34). The composite of all cause death or invasive 
or non-invasive mechanical ventilation occurred in 
23 patients (10.1%) in the therapeutic heparin group 
and 38 (16.0%) in the prophylactic heparin group 
(0.59, 0.34 to 1.02; P=0.06). No significant differences 
were found in time to the primary composite outcome, 
ICU admission, or mechanical ventilation between 
the groups (supplementary figs S2, S4, and S5). 
Differences in all cause death in favour of therapeutic 
heparin, however, emerged early during the first week 
of follow-up and continued to be apparent up to 28 
days (supplementary fig S3).
The mean number of ventilator-free days was 26.5 
(standard deviation 5.6) in the therapeutic heparin 
group and 24.7 (SD 8.5) in the prophylactic heparin 
group (odds ratio from ordinal logistic regression 1.77, 
95% confidence interval 1.02 to 3.08; P=0.042). The 
mean number of organ support-free days was 25.8 
(SD 6.2) in the therapeutic heparin group and 24.1 
(SD 8.8) in the prophylactic heparin group (odds ratio 
1.41, 95% confidence interval 0.90 to 2.21; P=0.13). 
The mean number of ICU-free days was 26.0 (SD 6.1) 
in the therapeutic heparin group and 24.2 (SD 8.8) in 
the prophylactic heparin group (1.51, 0.94 to 2.41; 
P=0.087). No relevant between group difference in 
hospital-free days was found (table 2).
Venous thromboembolism occurred in two patients 
(0.9%) in the therapeutic heparin group and six (2.5%) 
in the prophylactic heparin group (0.34, 0.07 to 1.71; 
P=0.19; table 2 and supplementary table S7). No fatal 
thromboembolic events occurred. D-dimer levels, 
assessed a median of 1.5 days (interquartile range 
1-2 days) after randomisation in 162 patients (71.1%) 
assigned to therapeutic heparin and 173 (73.0%) 
assigned to prophylactic heparin, were lower in the 
therapeutic heparin group (geometric mean ratio 0.88, 
95% confidence interval 0.78 to 0.99; P=0.03).
Safety outcomes
Major bleeding events occurred in two patients (0.9%) 
in the therapeutic heparin group and four (1.7%) 
in the prophylactic heparin group (odds ratio 0.52, 
95% confidence interval 0.09 to 2.85; P=0.69, table 
2). No fatal bleeding events or cases of intracranial 
haemorrhage occurred (supplementary tables S8 and 
S9).
Subgroup and sensitivity analyses
Prespecified subgroup analyses of the primary outcome 
and post hoc subgroup analyses of all cause death 
did not provide evidence for differences in treatment 
effect between subgroups (fig 2 and supplementary 
fig S6). Findings from the per protocol analyses and 
other sensitivity analyses, including an intention-to-
treat analysis of the primary outcome with time-by-
treatment interaction, were similar to those from the 
primary analysis (supplementary tables S10-S17).
Discussion
In this randomised trial of moderately ill patients 
with covid-19 and increased D-dimer levels admitted 
to hospital wards, therapeutic heparin was not 
associated with a significantly lower incidence of the 
primary composite of death, mechanical ventilation, 
or ICU admission compared with prophylactic heparin. 
The odds of all cause death in the group allocated 
to therapeutic heparin was, however, significantly 
reduced by 78%. Between group differences were 
smaller and non-significant for mechanical ventilation 
and ICU admission.
Comparison with other studies
The mortality reduction was more pronounced in 
RAPID than in a multiplatform trial of moderately 
ill patients with covid-19 admitted to hospital, 
integrating the Antithrombotic Therapy to Ameliorate 
Complications of COVID-19 (ATTACC), Accelerating 
COVID-19 Therapeutic Interventions and Vaccines-4 
Antithrombotics Inpatient Platform Trial (ACTIV-
4a), and the Randomized, Embedded, Multifactorial 
Adaptive Platform Trial for Community-Acquired 
Pneumonia (REMAP-CAP).19 Potential explanations 
include chance and a stronger contrast between 
treatment arms in RAPID compared with the 
multiplatform trial.19 28 The multiplatform trial 
allowed intermediate dose heparin in the control 
group, and 28.3% of participants received higher than 
prophylactic doses.19 In addition, 20.4% participants 
in the experimental group received lower than 
therapeutic heparin doses.19 RAPID only allowed 
prophylactic heparin doses in the control group, and 
only 1.7% of participants received higher doses with 
no clear clinical indication. Similarly, only 2.6% 
received lower than therapeutic heparin doses in the 
experimental group (supplementary tables S18 and 
S19). It is unlikely that the difference in eligibility 
criteria for increased D-dimer levels between RAPID 
and the multiplatform trial account for the larger 
reduction in deaths in RAPID. The multiplatform trial 
did not find a treatment-by-subgroup interaction for 
any of the outcomes, including all cause death, when 
distinguishing between patients who were D-dimer 
positive, D-dimer negative, or had unknown D-dimer 
levels.19 Both trials excluded patients at higher risk 
of bleeding and thrombosis, and those who were 
receiving mechanical ventilation at screening.21 29 
The effectiveness of anticoagulation seems to depend 
on the type of anticoagulant: the Anticoagulation 
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Coronavirus (ACTION) trial used 15-20 mg of 
rivaroxaban in 94% of patients assigned to therapeutic 
anticoagulation, and found no benefit.30 Rivaroxaban 
is unlikely to have the anti-inflammatory and antiviral 
properties attributed to heparin.2 11-15 In addition, 
ACTION allowed intermediate doses of enoxaparin 
in the control group. Nevertheless, given variation 
in findings from published trials, prospective meta-
analyses will be important to determine the effects of 
different types and doses of anticoagulants in different 
patient subgroups.31 32
The trial was conducted during a 12 month period 
between May 2020 and May 2021. During this time, 
management strategies for covid-19 have evolved, 
which in turn could have influenced the effect of 
therapeutic heparin on clinical outcomes. However, we 
found no time-by-treatment interaction in a sensitivity 
analysis (supplementary table S15). In RAPID and 
the multiplatform trials, lower rates of major bleeding 
compared with those in cohort studies were observed, 
suggesting that investigators were able to exclude 
patients with higher risks of bleeding.19 20 A numerical 
increase in bleeding risk with prophylactic heparin 
in this trial is most probably a chance finding; 95% 
confidence intervals are wide and compatible with the 
increased risk of bleeding associated with therapeutic 
heparin in the multiplatform trial by Lawler et al.19 In 
fact, one of the patients in the prophylactic heparin 
group experienced a major bleed after hospital discharge 
while not receiving any form of anticoagulation. 
The event was reported, as it occurred within the 28 
day observation period. The reason for low venous 
thromboembolic events in this and other trials is unclear 
(2.2% overall in RAPID, 1.9% in the multiplatform 
trial in moderately ill patients,19 4.7% in ACTION),30 
but could reflect eligibility criteria or improvements 
in therapies addressing inflammatory and thrombotic 
processes, compared with earlier studies.17 19 30 33
Limitations of this study
Our trial has several limitations. RAPID had an adaptive 
design. The protocol prespecified that the sample size 
would be increased if the conditional power at 75% of 
the original sample size was between 60% and 80%.21 
The conditional power was, however, below 60%, 
therefore the sample size was not increased and RAPID 
remained underpowered for the analysis of the primary 
outcome. Despite encouraging early observational data 
from Wuhan, China,2 we did not consider all cause 
death as a primary outcome, as the sample size required 
Table 2 | Primary and secondary outcomes of moderately ill patients with covid-19 admitted to hospital wards, 
according to treatment assignment
Outcomes
No (%) of patients
Odds ratio or geometric 






Primary composite outcome* 37 (16.2) 52 (21.9) 0.69 (0.43 to 1.10) 0.12
Secondary outcomes
Death from any cause 4 (1.8) 18 (7.6) 0.22 (0.07 to 0.65) 0.006
Invasive mechanical ventilation 11 (4.8) 16 (6.8) 0.70 (0.32 to 1.55) 0.38
Any mechanical ventilation† 21 (9.2) 26 (11.0) 0.82 (0.45 to 1.51) 0.53
ICU admission 33 (14.5) 42 (17.7) 0.79 (0.48 to 1.29) 0.34
Death or any mechanical ventilation 23 (10.1) 38 (16.0) 0.59 (0.34 to 1.02) 0.06
Death or ICU admission 36 (15.8) 50 (21.1) 0.70 (0.44 to 1.13) 0.14
Mean (SD) ventilator-free days 26.5 (5.6) 24.7 (8.5) 1.77 (1.02 to 3.08) 0.042
Mean (SD) organ support-free days 25.8 (6.2) 24.1 (8.8) 1.41 (0.90 to 2.21) 0.13
Mean (SD) ICU-free days 26.0 (6.1) 24.2 (8.8) 1.51 (0.94 to 2.41) 0.087
Mean (SD) hospital-free days 19.8 (7.3) 18.4 (9.2) 1.09 (0.79 to 1.50) 0.59
Renal replacement therapy‡ 2 (0.9) 5 (2.1) 0.41 (0.08 to 2.15) 0.29
Thromboembolism§:
 Venous 2 (0.9) 6 (2.5) 0.34 (0.07 to 1.71) 0.19
 Arterial 0 (0.0) 1 (0.4) - -
Bleeding:
 ISTH major bleeding¶ 2 (0.9) 4 (1.7) 0.52 (0.09 to 2.85) 0.69
 Red blood cell transfusion (≥1 unit) 3 (1.3) 9 (3.8) 0.34 (0.09 to 1.27) 0.14
  Transfusion of other blood components or products** 1 (0.4) 0 (0.0) - -
Heparin induced thrombocytopenia 0 (0.0) 0 (0.0) - -
Geometric mean (SD) D-dimer ratio (D-dimer×ULN)†† 1.9 (0.7) 2.4 (0.9) 0.88 (0.78 to 0.99) 0.032
ICU=intensive care unit; SD=standard deviation; ISTH=International Society on Thrombosis and Haemostasis.
All clinical outcomes were assessed up to 28 days post-randomisation. Analyses of all outcomes with exception of D-dimer ratio (D-dimer×ULN), 
ventilator-free, organ support-free, ICU-free, and hospital-free days alive were repeated for the timeframe up to hospital discharge and are shown in 
supplementary table S20.
*Defined as death, invasive mechanical ventilation, non-invasive mechanical ventilation, or ICU admission.
†Invasive or non-invasive (bilevel or continuous positive airway pressure) mechanical ventilation.
‡Continuous renal replacement therapy or intermittent haemodialysis.
§All diagnostically confirmed except for one symptomatic deep vein thrombosis event in the prophylactic heparin group, which could not be definitively 
confirmed because diagnostic imaging was not done during acute symptomatic period.
¶Major bleeding defined by the ISTH Scientific and Standardization Committee.
**Transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipitate and/or fibrinogen concentrate; 17 patients received 
convalescent plasma and were not included in the count.
††Geometric mean ratio defined as ratio of geometric means of D-dimer ratios (D-dimer×ULN) of day 2 ±24 hours post-randomisation, adjusted for 
baseline geometric means of D-dimer ratios using analysis of covariance. SD for the natural logarithm of D-dimer ratios at day 2 ±24 hours. Data for day 2 
±24 hours D-dimer were missing for 66 patients in the therapeutic heparin group and 64 in the prophylactic heparin group.
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to appropriately power the trial for this outcome 
would not have been feasible. Rather, we developed a 
primary composite outcome that would capture death, 
severe disease, and relevant health care utilisation 
irrespective of setting and available resources across 
geographical locations and pandemic waves. At the 
time of trial design in March and April 2020, covid-19 
was essentially an unknown entity with no known 
effective treatments. At this time, about 25% of patients 
admitted to the hospital in Ontario, Canada, were 
subsequently admitted to the ICU and an additional 
10% of patients died in-hospital without previous ICU 
admission.34 35 Taken together, this would have resulted 
in an average risk of the composite of death or ICU 
admission of 35%. Based on early data from Wuhan, 
China,2 we anticipated that the event rate in the control 
group could reach 50% if D-dimer levels were used for 
enrichment. To account for the uncertainty at the time 
of trial design, we additionally used an adaptive design 
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Fig 2 | Subgroup analysis of the primary outcome (a composite of death, invasive mechanical ventilation, non-invasive mechanical ventilation, or 
admission to an intensive care unit). Subgroup specific odds ratios derived from logistic regression. Circles represent point estimates and whiskers 
represent 95% confidence intervals. Odds ratio <1.0 favours therapeutic heparin. BMI=body mass index; ULN=upper limit of normal
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Given the potential for overburdening resource 
limited healthcare systems during the pandemic, it was 
not considered feasible to conduct a double blind trial. 
However, ICU admission and non-invasive mechanical 
ventilation as components of the primary composite 
outcome might have been too subjective and open to 
performance bias or random variation. Performance 
bias36 could have occurred if clinicians had been 
influenced in their decision to admit patients to ICU or 
treat them with non-invasive mechanical ventilation 
by their knowledge of the allocated treatment; random 
variation could have been caused by the pandemic’s 
variable impact on hospital resources over time and 
across regions. Detection bias36 could have occurred if 
investigation or reporting of potential events (especially 
incidental deep vein thromboses) in patients receiving 
therapeutic heparin was less likely than events in patients 
receiving prophylactic heparin. The converse could 
have been true for bleeding events. Biased reporting 
is unlikely to have occurred for the components of the 
primary outcome as admission to ICU and mechanical 
ventilation are unambiguously supported by medical 
source documents and all cause death is objective. 
Also, an independent clinical events committee 
blindly adjudicated all relevant outcomes. As in other 
anticoagulation trials in patients with covid-19,19 20 30 37 
many screened patients were not deemed eligible or did 
not consent to participate. Our findings might therefore 
not be generalisable to all moderately ill patients with 
covid-19 admitted to hospital wards.
Conclusions
The RAPID trial did not find a significant reduction in 
the primary composite outcome of death, mechanical 
ventilation, or ICU admission with therapeutic 
heparin. However, therapeutic heparin was associated 
with a substantially decreased odds of all cause death 
and low risk of major bleeding. In conjunction with the 
recently published multiplatform trial,19 the RAPID 
trial therefore suggests that therapeutic heparin is 
beneficial in moderately ill patients with covid-19 
admitted to hospital wards.
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